FMP

FMP

Enter

EWTX - Edgewise Therapeutics, Inc.

Profile of Edgewise Therapeutics, Inc.(EWTX), Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musc

photo-url-https://financialmodelingprep.com/image-stock/EWTX.png

Edgewise Therapeutics, Inc.

EWTX

NASDAQ

17.85 USD

-0.11 (-0.616%)

About

ceo

Dr. Kevin Koch Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.edgewisetx.com

exchange

NASDAQ

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

CIK

0001710072

ISIN

US28036F1057

CUSIP

28036F105

Address

3415 Colorado Avenue

Phone

303 735 8373

Country

US

Employee

88

IPO Date

Mar 26, 2021

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep